Skip to main content
SpringerLink
Log in

The Emerging Relevance of the Gut Microbiome in Cardiometabolic Health

  • Invited Commentary
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mindell DP. Phylogenetic consequences of symbioses: eukarya and eubacteria are not monophyletic taxa. Biosystems. 1992;27:53–62.

    Article  PubMed  CAS  Google Scholar 

  2. Lederberg J. Infectious history. Science. 2000;288:287–93.

    Article  PubMed  CAS  Google Scholar 

  3. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013;34:39–58.

    Article  PubMed  CAS  Google Scholar 

  4. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14:575–85.

    Article  PubMed  CAS  Google Scholar 

  5. Symons JD, Abel ED. Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide. Rev Endocr Metab Disord. 2013;14:59–68.

    Article  PubMed  CAS  Google Scholar 

  6. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–31.

    Article  PubMed  Google Scholar 

  7. Claus SP, Tsang TM, Wang Y, Cloarec O, Skordi E, Martin FP, et al. Systemic multi-compartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol. 2008;4:219.

    Article  PubMed  Google Scholar 

  8. Caesar R, Fåk F, Bäckhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med. 2010;268:320–8.

    Article  PubMed  CAS  Google Scholar 

  9. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.

    Article  PubMed  CAS  Google Scholar 

  10. Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498:99–103.

    Article  PubMed  CAS  Google Scholar 

  11. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–6.

    Article  PubMed  Google Scholar 

  12. Karlsson FH, Fåk F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245.

    Article  PubMed  Google Scholar 

  13. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576–85.

    Article  PubMed  CAS  Google Scholar 

  14. Bennett BJ, de Aguiar Vallim TQ, Wang Z, Shih DM, Meng Y, Gregory J, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013;17:49–60.

    Article  PubMed  CAS  Google Scholar 

  15. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575–84.

    Article  PubMed  CAS  Google Scholar 

  16. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499:97–101.

    Article  PubMed  CAS  Google Scholar 

  17. Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, Nguyen UT, et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One. 2011;6:e25482.

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Martin Obin declares that he has no conflict of interest. Laurence D Parnell declares that he has no conflict of interest. Jose M Ordovas declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the U.S. Department of Agriculture. The USDA is an equal opportunity provider and employer.

Author information

Authors and Affiliations

  1. Jean Mayer-USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA

    Martin Obin, Laurence D. Parnell & Jose M. Ordovas

Authors
  1. Martin Obin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurence D. Parnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jose M. Ordovas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurence D. Parnell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Obin, M., Parnell, L.D. & Ordovas, J.M. The Emerging Relevance of the Gut Microbiome in Cardiometabolic Health. Curr Cardiovasc Risk Rep 7, 425–426 (2013). https://doi.org/10.1007/s12170-013-0357-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12170-013-0357-2

Keywords

Search

Navigation